These inhibitory interactions included PVR (CD155) expressed by the tumor cells, but not by the other immune cells, and its receptors TIGIT and CD96 expressed by the anti-MAA T cells and not by the bystander cells, rendering anti-TIGIT therapy as an interesting target to invigorate anti-MAA T cells and not bystanders (Fig. 2f). Here, CD96 is linked to neoplasm.